Affluent Medical Sas Stock EBITDA

AFME Stock   1.66  0.01  0.60%   
Affluent Medical SAS fundamentals help investors to digest information that contributes to Affluent Medical's financial success or failures. It also enables traders to predict the movement of Affluent Stock. The fundamental analysis module provides a way to measure Affluent Medical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Affluent Medical stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Affluent Medical SAS Company EBITDA Analysis

Affluent Medical's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

EBITDA

 = 

Revenue

-

Basic Expenses

More About EBITDA | All Equity Analysis

Current Affluent Medical EBITDA

    
  (9.87 M)  
Most of Affluent Medical's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Affluent Medical SAS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Competition

According to the company disclosure, Affluent Medical SAS reported earnings before interest,tax, depreciation and amortization of (9.87 Million). This is 101.12% lower than that of the Healthcare sector and 101.54% lower than that of the Medical Devices industry. The ebitda for all France stocks is 100.25% higher than that of the company.

Did you try this?

Run Latest Portfolios Now

   

Latest Portfolios

Quick portfolio dashboard that showcases your latest portfolios
All  Next Launch Module

Affluent Fundamentals

About Affluent Medical Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Affluent Medical SAS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Affluent Medical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Affluent Medical SAS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Affluent Stock

Affluent Medical financial ratios help investors to determine whether Affluent Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Affluent with respect to the benefits of owning Affluent Medical security.